Intramyocardial injection of naked DNA encoding HIF-1α/VP16 hybrid to enhance angiogenesis in an acute myocardial infarction model in the rat

Kou Gi Shyu, Mei Ti Wang, Bao Wei Wang, Chih Chuna Chang, Jyh Gang Leu, Peiliang Kuan, Hang Chang

Research output: Contribution to journalArticle

159 Citations (Scopus)

Abstract

Objectives: The therapeutic utility of hypoxia-inducible factor-1 (HIF-1) transcriptional regulatory system for ischemic hindlimb has been demonstrated. It is not yet known whether this transcriptional regulatory system can be used as a therapeutic strategy to enhance collateral vessel formation in myocardial tissues, where acute hypoxia occurs due to inadequate perfusion. We aimed to test the hypothesis that exogenous administration of HIF-1α/VP16 could enhance collateral vessel formation in a rat acute myocardial infarction model. Methods: Sprague-Dawley rats received ligation of the proximal left anterior descending coronary artery to induce acute myocardial infarction. Immediately after the ligation, 50 μg total plasmid DNA (control, plasmid encoding human vascular endothelial growth factor (pVEGF165), or pHIF-1α/VP16) was injected into the infarct area at three locations. Results: Reverse transcription-polymerase chain reaction (RT-PCR) showed the presence of HIF-1α and VEGF mRNA in the myocardium, but not in other organs at days 3 and 7. The infarct size significantly decreased from 37±4% (control) to 24±2% in the VEGF-treated group and 23±2% in the HIF-1α/VP16 treated group (P2 (control) to 850±75/mm2 in the VEGF group and 850±50/mm2 in the HIF-1α/VP16-treated group (P2) than treatment with either therapy alone. Regional myocardial blood flow was also higher in the treated groups than in the control. Plasma levels of VEGF were also significantly higher in the HIF-1α/VP16 and VEGF-treated group than in the control group. Conclusions: The HIF-1α/VP16 hybrid transcription factor is able to reduce infarct size and enhance neovascularization in an acute ischemic myocardium. The potency of VEGF and HIF-1α/VP16 hybrid as therapeutic angiogenic factors in acute hypoxic myocardium is similar.

Original languageEnglish
Pages (from-to)576-583
Number of pages8
JournalCardiovascular Research
Volume54
Issue number3
DOIs
Publication statusPublished - 2002
Externally publishedYes

Fingerprint

Hypoxia-Inducible Factor 1
Myocardial Infarction
Vascular Endothelial Growth Factor A
Injections
DNA
Myocardium
Control Groups
Ligation
Plasmids
Therapeutics
Angiogenesis Inducing Agents
Regional Blood Flow
Hindlimb
Reverse Transcription
Sprague Dawley Rats
Coronary Vessels
Transcription Factors
Perfusion
Polymerase Chain Reaction
Messenger RNA

Keywords

  • Angiogenesis
  • Collateral circulation
  • Gene therapy
  • Infarction

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Intramyocardial injection of naked DNA encoding HIF-1α/VP16 hybrid to enhance angiogenesis in an acute myocardial infarction model in the rat. / Shyu, Kou Gi; Wang, Mei Ti; Wang, Bao Wei; Chang, Chih Chuna; Leu, Jyh Gang; Kuan, Peiliang; Chang, Hang.

In: Cardiovascular Research, Vol. 54, No. 3, 2002, p. 576-583.

Research output: Contribution to journalArticle

Shyu, Kou Gi ; Wang, Mei Ti ; Wang, Bao Wei ; Chang, Chih Chuna ; Leu, Jyh Gang ; Kuan, Peiliang ; Chang, Hang. / Intramyocardial injection of naked DNA encoding HIF-1α/VP16 hybrid to enhance angiogenesis in an acute myocardial infarction model in the rat. In: Cardiovascular Research. 2002 ; Vol. 54, No. 3. pp. 576-583.
@article{409a0ed310874fd0a52f00d94a844cb7,
title = "Intramyocardial injection of naked DNA encoding HIF-1α/VP16 hybrid to enhance angiogenesis in an acute myocardial infarction model in the rat",
abstract = "Objectives: The therapeutic utility of hypoxia-inducible factor-1 (HIF-1) transcriptional regulatory system for ischemic hindlimb has been demonstrated. It is not yet known whether this transcriptional regulatory system can be used as a therapeutic strategy to enhance collateral vessel formation in myocardial tissues, where acute hypoxia occurs due to inadequate perfusion. We aimed to test the hypothesis that exogenous administration of HIF-1α/VP16 could enhance collateral vessel formation in a rat acute myocardial infarction model. Methods: Sprague-Dawley rats received ligation of the proximal left anterior descending coronary artery to induce acute myocardial infarction. Immediately after the ligation, 50 μg total plasmid DNA (control, plasmid encoding human vascular endothelial growth factor (pVEGF165), or pHIF-1α/VP16) was injected into the infarct area at three locations. Results: Reverse transcription-polymerase chain reaction (RT-PCR) showed the presence of HIF-1α and VEGF mRNA in the myocardium, but not in other organs at days 3 and 7. The infarct size significantly decreased from 37±4{\%} (control) to 24±2{\%} in the VEGF-treated group and 23±2{\%} in the HIF-1α/VP16 treated group (P2 (control) to 850±75/mm2 in the VEGF group and 850±50/mm2 in the HIF-1α/VP16-treated group (P2) than treatment with either therapy alone. Regional myocardial blood flow was also higher in the treated groups than in the control. Plasma levels of VEGF were also significantly higher in the HIF-1α/VP16 and VEGF-treated group than in the control group. Conclusions: The HIF-1α/VP16 hybrid transcription factor is able to reduce infarct size and enhance neovascularization in an acute ischemic myocardium. The potency of VEGF and HIF-1α/VP16 hybrid as therapeutic angiogenic factors in acute hypoxic myocardium is similar.",
keywords = "Angiogenesis, Collateral circulation, Gene therapy, Infarction",
author = "Shyu, {Kou Gi} and Wang, {Mei Ti} and Wang, {Bao Wei} and Chang, {Chih Chuna} and Leu, {Jyh Gang} and Peiliang Kuan and Hang Chang",
year = "2002",
doi = "10.1016/S0008-6363(02)00259-6",
language = "English",
volume = "54",
pages = "576--583",
journal = "Cardiovascular Research",
issn = "0008-6363",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Intramyocardial injection of naked DNA encoding HIF-1α/VP16 hybrid to enhance angiogenesis in an acute myocardial infarction model in the rat

AU - Shyu, Kou Gi

AU - Wang, Mei Ti

AU - Wang, Bao Wei

AU - Chang, Chih Chuna

AU - Leu, Jyh Gang

AU - Kuan, Peiliang

AU - Chang, Hang

PY - 2002

Y1 - 2002

N2 - Objectives: The therapeutic utility of hypoxia-inducible factor-1 (HIF-1) transcriptional regulatory system for ischemic hindlimb has been demonstrated. It is not yet known whether this transcriptional regulatory system can be used as a therapeutic strategy to enhance collateral vessel formation in myocardial tissues, where acute hypoxia occurs due to inadequate perfusion. We aimed to test the hypothesis that exogenous administration of HIF-1α/VP16 could enhance collateral vessel formation in a rat acute myocardial infarction model. Methods: Sprague-Dawley rats received ligation of the proximal left anterior descending coronary artery to induce acute myocardial infarction. Immediately after the ligation, 50 μg total plasmid DNA (control, plasmid encoding human vascular endothelial growth factor (pVEGF165), or pHIF-1α/VP16) was injected into the infarct area at three locations. Results: Reverse transcription-polymerase chain reaction (RT-PCR) showed the presence of HIF-1α and VEGF mRNA in the myocardium, but not in other organs at days 3 and 7. The infarct size significantly decreased from 37±4% (control) to 24±2% in the VEGF-treated group and 23±2% in the HIF-1α/VP16 treated group (P2 (control) to 850±75/mm2 in the VEGF group and 850±50/mm2 in the HIF-1α/VP16-treated group (P2) than treatment with either therapy alone. Regional myocardial blood flow was also higher in the treated groups than in the control. Plasma levels of VEGF were also significantly higher in the HIF-1α/VP16 and VEGF-treated group than in the control group. Conclusions: The HIF-1α/VP16 hybrid transcription factor is able to reduce infarct size and enhance neovascularization in an acute ischemic myocardium. The potency of VEGF and HIF-1α/VP16 hybrid as therapeutic angiogenic factors in acute hypoxic myocardium is similar.

AB - Objectives: The therapeutic utility of hypoxia-inducible factor-1 (HIF-1) transcriptional regulatory system for ischemic hindlimb has been demonstrated. It is not yet known whether this transcriptional regulatory system can be used as a therapeutic strategy to enhance collateral vessel formation in myocardial tissues, where acute hypoxia occurs due to inadequate perfusion. We aimed to test the hypothesis that exogenous administration of HIF-1α/VP16 could enhance collateral vessel formation in a rat acute myocardial infarction model. Methods: Sprague-Dawley rats received ligation of the proximal left anterior descending coronary artery to induce acute myocardial infarction. Immediately after the ligation, 50 μg total plasmid DNA (control, plasmid encoding human vascular endothelial growth factor (pVEGF165), or pHIF-1α/VP16) was injected into the infarct area at three locations. Results: Reverse transcription-polymerase chain reaction (RT-PCR) showed the presence of HIF-1α and VEGF mRNA in the myocardium, but not in other organs at days 3 and 7. The infarct size significantly decreased from 37±4% (control) to 24±2% in the VEGF-treated group and 23±2% in the HIF-1α/VP16 treated group (P2 (control) to 850±75/mm2 in the VEGF group and 850±50/mm2 in the HIF-1α/VP16-treated group (P2) than treatment with either therapy alone. Regional myocardial blood flow was also higher in the treated groups than in the control. Plasma levels of VEGF were also significantly higher in the HIF-1α/VP16 and VEGF-treated group than in the control group. Conclusions: The HIF-1α/VP16 hybrid transcription factor is able to reduce infarct size and enhance neovascularization in an acute ischemic myocardium. The potency of VEGF and HIF-1α/VP16 hybrid as therapeutic angiogenic factors in acute hypoxic myocardium is similar.

KW - Angiogenesis

KW - Collateral circulation

KW - Gene therapy

KW - Infarction

UR - http://www.scopus.com/inward/record.url?scp=0036275028&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036275028&partnerID=8YFLogxK

U2 - 10.1016/S0008-6363(02)00259-6

DO - 10.1016/S0008-6363(02)00259-6

M3 - Article

C2 - 12031703

AN - SCOPUS:0036275028

VL - 54

SP - 576

EP - 583

JO - Cardiovascular Research

JF - Cardiovascular Research

SN - 0008-6363

IS - 3

ER -